Pembrolizumab vs Chemotherapy for Platinum-Pretreated Recurrent/Metastatic Nasopharyngeal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Ann. Oncol 2022 Dec 16;[EPub Ahead of Print], ATC Chan, VHF Lee, RL Hong, MJ Ahn, WQ Chong, SB Kim, GF Ho, PB Caguioa, N Ngamphaiboon, C Ho, MASA Aziz, QS Ng, CJ Yen, N Soparattanapaisarn, RK Ngan, SK Kho, MLA Tiambeng, T Yun, V Sriuranpong, AP Algazi, A Cheng, E Massarelli, RF Swaby, S Saraf, J Yuan, LL SiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.